Trials / Completed
CompletedNCT00336921
Alfuzosin for Treating Acute Urinary Retention
A Double-blind, Randomized,Placebo Controlled Study of Alfuzosin 10mg od in the Return to Successful Voiding in Patients With a First Episode of Acute Urinary Retention Due to Benign Prostatic Hyperplasia
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 156 (actual)
- Sponsor
- Sanofi · Industry
- Sex
- Male
- Age
- 50 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of the study is to assess the efficacy of alfuzosin 10mg daily in the return to successful voiding after removal of the catheter following a first episode of acute urinary retention (AUR) in patients suffering from benign prostatic hyperplasia (BPH).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Alfuzosin | Once daily |
| DRUG | Placebo | Once daily |
Timeline
- Start date
- 2006-02-01
- Primary completion
- 2007-04-01
- First posted
- 2006-06-15
- Last updated
- 2009-09-15
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT00336921. Inclusion in this directory is not an endorsement.